Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium

AIMS OF THE STUDY: Thrombopoietin receptor agonists (TPO-RAs) are approved for immune thrombocytopenia (ITP), but their impact on health-related quality of life (HRQoL) remains poorly investigated in clinical practice. This observational study aimed to gain insight into real-world patient-reported e...

Descripción completa

Detalles Bibliográficos
Autores principales: Rovó, Alicia, Cantoni, Nathan, Samii, Kaveh, Rüfer, Axel, Koenen, Giedre, Ivic, Sandra, Cavanna, Davide, Benz, Rudolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022837/
https://www.ncbi.nlm.nih.gov/pubmed/35446925
http://dx.doi.org/10.1371/journal.pone.0267342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022837/
https://www.ncbi.nlm.nih.gov/pubmed/35446925
http://dx.doi.org/10.1371/journal.pone.0267342

Ejemplares similares